Drug profile · INN
olmesartan medoxomil
BENICAR
olmesartan medoxomil (BENICAR) is a type-1 angiotensin ii receptor antagonist. Associated with Amneal Pharma Europe Ltd. Route of administration: oral. Current US regulatory status: approved.
Drug details — olmesartan medoxomil
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 2
- Data quality
- 0.89
Quick answer
olmesartan medoxomil (BENICAR) is a type-1 angiotensin ii receptor antagonist. Associated with Amneal Pharma Europe Ltd. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Type-1 angiotensin II receptor antagonist
Primary target: Type-1 angiotensin II receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is olmesartan medoxomil?
olmesartan medoxomil (BENICAR) is a type-1 angiotensin ii receptor antagonist. Associated with Amneal Pharma Europe Ltd. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for olmesartan medoxomil?
BENICAR is a marketed brand name for olmesartan medoxomil. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of olmesartan medoxomil?
olmesartan medoxomil has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.